Daratumumab shows promise as an addition to AL amyloidosis therapy

Adding daratumumab to bortezomib-containing therapy improves outcomes for people with newly-diagnosed immunoglobulin light-chain (AL) amyloidosis, a new study has shown. The CD38-targeted therapy increased haematologic complete response rates and survival free from major organ deterioration or haematologic progression in the international phase 3 ANDROMEDA trial, which included Australian centres. The study compared haematologic responses in ...

Already a member?

Login to keep reading.

© 2021 the limbic